Ear specialist Otonomy nets $49m from position of strength
This article was originally published in Scrip
Executive Summary
The ear disease-focused biotechnology firm Otonomy raised more than originally planned with its $49m Series D venture capital round, but the San Diego-based company courted investors from a position of strength while it still had money from its recent Series C round in the bank.